Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Moderna 0.145, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Moderna vs CSL Net Worth and Market Cap
Moderna (MRNA) and CSL (CSL.AX) are peers in Vaccines. Moderna reported revenue of $145M as of Q2 2026, compared with $7.3B for CSL. CSL leads on revenue.
Moderna's gross margin is 35.9% versus 44.4% for CSL. Moderna's net margin is -539.3% versus -40.2% for CSL.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Moderna +2.1%, CSL +0.7%.
- CSL made an operating profit in its latest quarter (19.0% margin); Moderna made an operating loss (-562.1%).
- Moderna's KPIs on Sterling include Cash, Cash Equivalents and Investments (Quarterly) and Net Product Sales vs Deferred Revenue (Quarterly).
- CSL's KPIs on Sterling include Behring Revenue by Therapy (Annual) and Behring IVIG vs SCIG Revenue (Annual).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Moderna, CSL.| Metric | Moderna | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $145.00M | $7.30B |
| Cost of Revenue | $93.00M | $4.06B |
| Gross Profit | $52.00M | $3.24B |
| Operating Income | $-815.00M | $1.39B |
| Net Income | $-782.00M | $-2.94B |
| R&D Expense | $651.00M | $614.00M |
| Earnings Per Share | -$1.96 | -$6.14 |
| Gross Margin | 35.9% | 44.4% |
| Operating Margin | -562.1% | 19.0% |
| Net Profit Margin | -539.3% | -40.2% |
| Free Cash Flow | $-563.00M | $1.76B |
| Cumulative Free Cash Flow | $7.37B | $21.56B |
| Operating Cash Flow | $-526.00M | $2.09B |
| Cash & Equivalents | $1.72B | $1.51B |